Today marks a significant milestone for VitaVitro as its independently developed embryo culture medium, VitaVitro® 1-step Culture Media, has received the national third-class medical device registration certificate (National Medical Device Approval No. 20233180789). This approval makes it the first one-step culture medium developed by a Chinese enterprise for the culture from fertilized eggs to the blastocyst stage.
A Trusted Product
Embryo culture medium is one of VitaVitro's flagship products, known for its exceptional performance and reliability. It has been sold in overseas markets for years, earning widespread praise from customers. Before receiving approval from the National Medical Products Administration (NMPA), VitaVitro conducted the first prospective, multi-center, randomized controlled trial (RCT) of this embryo culture medium in China. The trial results exceeded those of the control product, further validating the medium's superior performance.
Technical Innovation
For a long time, VitaVitro has focused on addressing key industry challenges, providing innovative solutions in areas such as vitrification cryopreservation and embryo culture. The certification of this embryo culture medium represents a major breakthrough, establishing VitaVitro's leadership in technological innovation. This achievement not only underscores the company's advanced capabilities but also sets a higher development platform for both VitaVitro and the broader industry, promoting technological progress and research achievements in reproductive medicine.
This approval signifies a new era for VitaVitro, highlighting its commitment to advancing reproductive medicine through cutting-edge solutions.